Medical Technology Breaking News: Aethlon Medical (OTCBB:
AEMD) Announces Effectiveness of Reverse Stock Split
SAN DIEGO - April 14, 2015 (Investorideas.com newswire)
Aethlon Medical, Inc. (OTCBB:AEMD),
a pioneer in developing targeted therapeutic devices to address infectious
diseases and cancer, announced today that its previously disclosed 1-for-50
reverse stock split is effective as of today, April 14, 2015, and that the
Company's common stock will begin trading on a split-adjusted basis when the
market opens today. The Company's common stock will trade on a split-adjusted
basis under the temporary symbol "AEMDD," with the "D"
appended to signify that the reverse stock split has occurred. The trading symbol
will revert to "AEMD" after approximately 20 trading days.
The
reverse split reduces the number of shares of the Company's common stock
outstanding from approximately 332 million to approximately 6.7 million.
Proportional adjustments were made to the Company's authorized shares, and will
be made to the terms and exercise price of outstanding options and warrants, as
well as the conversion terms of the Company's outstanding convertible notes.
Any fractional shares resulting from the reverse stock split will be rounded up
to the next whole share. The par value of the Company's common stock will
remain at $0.001 per share after the reverse stock split. The new CUSIP number
for the Company's common stock following the reverse stock split is 00808Y208.
INFORMATION FOR
STOCKHOLDERS
Stockholders
who have existing stock certificates will receive written instructions by mail
from the Company's transfer agent, Computershare. Stockholders who hold their
shares in brokerage accounts or "street name" are not required to
take any action to effect the exchange of their shares. Such stockholders will
be contacted by their brokers with instructions.
About Aethlon Medical, Inc.
Aethlon
Medical creates medical devices that target unmet therapeutic needs in
infectious disease and cancer. The company's lead product is the Aethlon
Hemopurifier®, a first-in-class device that selectively targets the rapid
elimination of circulating viruses and tumor-secreted exosomes that promote
cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that
is advancing exosome-based products to diagnose and monitor cancer, infectious
disease and neurological disorders. Additional information can be found on-line
at http://www.aethlonmedical.com/ and connect with
the Company on Twitter, LinkedIn, Facebook and Google+.
Certain
statements herein may be forward-looking and involve risks and uncertainties.
Such forward-looking statements involve assumptions, known and unknown risks,
uncertainties and other factors which may cause the actual results, performance
or achievements of Aethlon Medical, Inc. to be materially different from any
future results, performance, or achievements expressed or implied by the
forward-looking statements. Such potential risks and uncertainties include,
without limitation, that Exosome Sciences, Inc. will not be able to
commercialize its future products, including any that can be described as a
liquid biopsy, that the FDA will not approve the initiation of the Company's
clinical programs or provide market clearance of the company's products, future
human studies whether revenue or non-revenue generating of the Aethlon ADAPT™
system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient
responsiveness to established cancer or hepatitis C therapies or as a
standalone cancer or hepatitis C therapy or as a broad spectrum defense against
viral pathogens, including Ebola, the Company's ability to raise capital when
needed, the Company's ability to complete the development of its planned
products, the Company's ability to manufacture its products either internally
or through outside companies and provide its services, the impact of government
regulations, patent protection on the Company's proprietary technology, the
ability of the Company to meet the milestones contemplated in the DARPA
contract, product liability exposure, uncertainty of market acceptance,
competition, technological change, and other risk factors. In such instances,
actual results could differ materially as a result of a variety of factors,
including the risks associated with the effect of changing economic conditions
and other risk factors detailed in the Company's Securities and Exchange
Commission filings. The Company undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contacts:
David
Zazoff
MDM Worldwide Solutions
646-403-3554
MDM Worldwide Solutions
646-403-3554
Sign up
for the free investor news and stock alerts:
Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher
of news and research as well as creates original content as a news source.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Investorideas is a news source on Google news and
Linkedintoday plus hundreds of syndication partners. Our site does not make
recommendations for purchases or sale of stocks or products. Nothing on our
sites should be construed as an offer or solicitation to buy or sell products
or securities. All investment involves risk and possible loss of investment.
This site is currently compensated by featured companies, news submissions,
content marketing and online advertising. Contact each company directly for
press release questions. Disclosure is posted on each release if required but
otherwise the news was not compensated for and is published for the sole
interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Disclosure: AEMD
subscribes to the Investorideas newswire content publishing annual program
(9700 per Year, paid quarterly) for news publishing.
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
Become an Investorideas.com Member and access our 14 online stock
directories 24/7 –biotech, defense, mining stocks, oil and gas stocks and
more...
No comments:
Post a Comment